Aa
A
A
Close
Avatar universal
Hepatitis C Virus Genetics Researchers at Pfizer Inc. have published new data on Hepatitis C Virus Genetics GENOTYPE 1b/2a

April 12th, 2008

(NewsRx.com) -- A new study, 'Novel chimeric genotype 1b/2a hepatitis C virus suitable for high-throughput screening,' is now available. "A major obstacle in hepatitis C virus (HCV) research has been the lack of a permissive cell culture system that produces infectious viral particles. Significant breakthroughs have been achieved lately in establishing such culture systems," investigators in the United States report.
"Yet to date, there are no reports of the applications of any of these systems in HCV drug screening. Here, we report the generation of two monocistronic, chimeric genotype 1 full-length HCV genome molecules. These molecules, C33J-Y835C-UBI and C33J-Y835C-FMDV2A, both contain the structural protein region from genotype 1 (subtype 1b, Con1) and the remaining region from the genotype 2a (JFH1) clone. Both contain the humanized Renilla luciferase reporter gene which is separated from the rest of the HCV open reading frame by two different cleavage sites. The viral RNAs replicated efficiently in transfected cells. Viral particles produced were infectious in naïve Huh7.5 cells, and the infectivity could be blocked by monoclonal antibody against a putative HCV entry cofactor, CD81. A pilot high-throughput screen of 900 unknown compounds was executed by both the genotype 2a subgenomic replicon system and the infectious system. Thirty-one compounds were identified as hits by both systems, whereas 78 compounds were identified as hits only for the infectious system, suggesting that the infectious system is capable of identifying inhibitors targeting the viral structural proteins and steps involving them in the viral life cycle," wrote Y. Zhang and colleagues, Pfizer Inc.

The researchers concluded: "The infectious HCV system developed here provides a useful and versatile tool which should greatly facilitate the identification of HCV inhibitors currently not identified by the subgenomic replicon system."

Zhang and colleagues published their study in Antimicrobial Agents and Chemotherapy (Novel chimeric genotype 1b/2a hepatitis C virus suitable for high-throughput screening. Antimicrobial Agents and Chemotherapy, 2008;52(2):666-74).

For additional information, contact Y. Zhang, Pfizer Global Research and Development, Dept. of Exploratory Biology, La Jolla Laboratories, 10628 Science Center Drive, San Diego, CA 92121 USA..

The publisher of the journal Antimicrobial Agents and Chemotherapy can be contacted at: American Society Microbiology, 1752 N St. NW, Washington, DC 20036-2904, USA.

                                                                                                                                                           Ron

Cancel
0 Answers
Page 1 of 1
Your Answer
Avatar universal
Answer
Do you know how to answer? Tap here to leave your answer...
Answer
Answer
Post Answer
A
A
Recent Activity
Avatar universal
Blank
317787 tn?1473362051
Blank
Dee1956 Meegy 172 days!! Coincidenc... Comment
Dec 01
406584 tn?1399591666
Blank
10356 commented on stilltrying1965's status
Dec 01
Blank
Weight Tracker
Track your weight over time
Start Tracking Now
Top Hepatitis Answerers
317787 tn?1473362051
Blank
DC
163305 tn?1333672171
Blank
Rural Mural, CA
446474 tn?1446351282
Blank
San Francisco, CA
Avatar universal
Blank
1747881 tn?1358189534
Blank
Greeley, CO
2059648 tn?1439770265
Blank
Hepatitis C Community Resources